This study is on track to commence 2Q’CY22
with results due Q3’CY22. Sales of the dystrophin restoration drugs in the US in 2021 were in excess
of US$700m.
Feel like this might deliver early Q3. Huge potential and perhaps... interest by others?!
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 8.0¢ | 7.7¢ | $134.7K | 1.732M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99278 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 122500 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.0¢ | 7.7¢ | 70281 | ||
| Last updated 15.51pm 07/05/2024 ? | |||||
| PER (ASX) Chart |